Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Measurable Residual Disease Clear all
Completed Phase 3 Interventional Results available

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

NCT03901963
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
70
States / cities
Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Not yet recruiting Phase 2 Interventional

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

NCT07566364
View directory record Official record
Conditions
Lymphocytic Leukemia
Interventions
Mosunetuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

NCT06333678
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

NCT03863184
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Lenalidomide, Rituximab, Obinutuzumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

NCT02477878
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
Interventions
BPX-501, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 23, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

NCT04876248
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Lenalidomide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

NCT04634435
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Combination Product
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Caris Biorepository Research Protocol

NCT01499394
View directory record Official record
Conditions
Cancer, Early Detection of Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Caris Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2035
U.S. locations
38
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

NCT00923013
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Cladribine, Rituximab, BMbx, MRI, EKG, Echocardiogram, Abdominal/splenic ultrasound, Stress test
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Not yet recruiting Phase 2 Interventional

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

NCT07572929
View directory record Official record
Conditions
Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Interventions
Maintenance Therapy, No intervention
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT05289687
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia
Interventions
Daratumumab / Hyaluronidase Injection
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

NCT02458014
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
Interventions
Blinatumomab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT03326921
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Biphenotypic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995
View directory record Official record
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional Results available

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

NCT01743807
View directory record Official record
Conditions
Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
Interventions
GNKG168
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

NCT03441061
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting No phase listed Observational

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Personalis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

NCT03509961
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Diagnostic Test · Drug
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

NCT07400029
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Obecabtagene Autoleucel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 10:47 PM EDT
Completed No phase listed Observational

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

NCT03488862
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Jul 23, 2026, 10:47 PM EDT
Completed No phase listed Observational

Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia

NCT00005619
View directory record Official record
Conditions
Leukemia
Interventions
polymerase chain reaction, flow cytometry, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Jul 23, 2026, 10:47 PM EDT
Recruiting Phase 2 Interventional

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT04523857
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Hydroxychloroquine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 10:47 PM EDT